An Essential Parameters of Fucosidosis Include History of the Disease, Other Lysosomal Storage Disease, Symptoms as well as Clinical Features, Treatment as well as Therapeutic Options

Abstract

Fucosidosis is a rare lysosomal storage disease occurred by α-L-fucosidase deficiency because of mutation especially in the FUCA1 gene. This enzyme plays an important role regarding catabolism of fucose-containing glycoproteins, glycolipids, and oligosaccharides within the lysosome. Fucose-rich substrates are deposited in lysosomes as a result of mutations in FUCA1, which cause either reduced enzyme activity or complete loss of function. Undigested substrates cause lysosomes to swell, leading to secondary storage problems that affect other metabolic pathways. The central nervous system is especially vulnerable,along with lysosomal dysfunction creating microglial activation, inflammation, and neuronal loss, resulting in the neurodegenerative symptoms of fucosidosis. Neuroinflammation contributes to secondary damage, along with neuronal apoptosis, axonal degeneration, and synaptic dysfunction, enhancing the disease process. Chronic neuroinflammation disrupts synaptic plasticity as well as neuronal survival, resulting in progressive intellectual disability, learning difficulties, and loss of previously acquired skills. Inflammatory cytokines and lysosomal burden in motor neurons and associated pathways contribute to ataxia, spasticity, and hypotonia, which are common motor symptoms in fucosidosis. Raised neuroinflammatory markers can enhance neuronal excitability, resulting in the frequent occurrence of epilepsy in affected individuals. So, fucosidosis is manifested by rapid mental and motor loss, along with growth retardation, coarse facial features, hepatosplenomegaly, telangiectasis or angiokeratomas, epilepsy, inguinal hernia, and dysostosis multiplex. Patients generally die at an early age. Treatment of fucosidosis is a great challenge, and there is currently no definitive effective treatment. Hematopoietic cell transplantation studies are ongoing regarding the treatment of fucosidosis. Whatever it may be, early diagnosis of this disease and treatment shows an effectiveness. In addition, the body’s immune system reduces because of chemotherapy applied after transplantation, leaving the body vulnerable to microbes and infections, and the risk of death is more along with this treatment. In another treatment method, gene therapy, the use of retroviral vectors, is enhancing because of their easy integration, high cell efficiency, and safety. Preclinical research is being conducted for fucosidosis using an alternative treatment strategy called enzyme replacement therapy; nevertheless, a significant disruption in lysosomal storage illnesses affecting the central nervous system is the blood–brain barrier. Due to the rapid advancement of fucosidosis, a rare disease, and the delay in diagnosing patients who have been identified thus far, early identification is crucial. Furthermore, the less dangerous enzyme replacement therapy shows promise.